Marksans Pharma's Q1 FY 2025-26 Quarterly Results

Result Summary

• Marksans Pharma Ltd reported a 8.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 3.3%.
• Its expenses for the quarter were up by 15.3% QoQ and 13.1% YoY.
• The net profit decreased 25.0% QoQ and decreased 34.7% YoY.
• The earnings per share (EPS) of Marksans Pharma Ltd stood at 1.3 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Marksans Pharma Ltd is a pharmaceutical company known for manufacturing and marketing a range of pharmaceutical formulations. The company operates primarily in the healthcare industry and is engaged in the production of over-the-counter (OTC) products, prescription drugs, and bulk formulations. Marksans Pharma has a global presence, serving markets in the United States, Europe, Australia, and other regions. The company focuses on providing high-quality and affordable healthcare solutions. Recent major developments in the company, if any, are not available from the provided data.

Revenue

In Q1FY26, Marksans Pharma Ltd reported a total income of ₹625.63 crores. This represents a quarter-over-quarter (QoQ) increase of 8.5% from ₹576.54 crores in Q4FY25. On a year-over-year (YoY) basis, total income grew by 3.3% compared to ₹605.57 crores in Q1FY25. The increase in revenue suggests a positive trend in income generation over the quarters and the year, indicating robust business operations and market demand.

Profitability

The profitability analysis of Marksans Pharma Ltd for Q1FY26 shows a profit before tax (PBT) of ₹76.60 crores, which is a decline of 23.6% QoQ from ₹100.28 crores in Q4FY25 and a 36.2% YoY decrease from ₹120.02 crores in Q1FY25. The company's tax expense for the quarter stood at ₹18.40 crores, showing an 18.7% decrease QoQ from ₹22.63 crores in Q4FY25 and a 40.5% decrease YoY from ₹30.95 crores in Q1FY25. The profit after tax (PAT) for Q1FY26 was ₹58.20 crores, reflecting a 25.0% decline QoQ and a 34.7% reduction YoY. The earnings per share (EPS) for the quarter was ₹1.30, down from ₹1.70 in Q4FY25 and ₹2.00 in Q1FY25, which corresponds to a QoQ decrease of 23.5% and a YoY decline of 35.0%.

Operating Metrics

The operating metrics of Marksans Pharma Ltd highlight total expenses of ₹549.03 crores in Q1FY26, which increased by 15.3% QoQ from ₹476.27 crores in Q4FY25 and by 13.1% YoY from ₹485.54 crores in Q1FY25. The increase in total expenses indicates higher operational costs or investments in business activities. These metrics reflect the financial dynamics of the company's operational performance over the specified periods. Additionally, the observed trends in income and expenses provide insights into the company's cost management and revenue generation strategies.